Photo of Omri Gottesman

Omri Gottesman

  • ADJUNCT ASSISTANT PROFESSOR Medicine, General Internal Medicine
Print ProfilePrint Profile


  • MD, University College London


    Dr. Gottesman is a UK-trained physician-scientist focused on the translation and implementation of genomic and data-driven medicine into clinical practice.


Research Interests:

  • Developing innovative tools to facilitate personalized medicine
  • Electronic phenotyping - clinical data capture and representation
  • Genomic and data-driven medicine - translation of genomics and clinical data into enhanced clinical prediction and clinical care through electronic health records and clinical decision support
  • Complex trait genomics and associated pharmacogenomics
  • Genomic medicine in heterogeneous populations
  • Clinical care implementation and evaluation of personalized medicine projects


Dr. Gottesman is currently leading the CLIPMERGE PGx program (CLinical Implementation of Personalized Medicine through Electronic health Records and GEnomics) at Mount Sinai. The CLIPMERGE program aims to implement a novel clinical decision support (CDS) engine for delivering guidelines for using genetic variants of clinical significance in a way that integrates with physician work processes. CLIPMERGE is an advanced information management system that is external to, but communicates with the Electronic Health Record and takes advantage of decision support capabilities executable at the point-of-care. The pilot study, CLIPMERGE PGx, is focused on pharmacogenomics and will consent 1500 Biobank participants undergoing routine care at Mount Sinai Medical Center and genotype them for known, common pharmacogenomic variation. These results will be made available to the patient's treating physician at the time they are prescribing certain medications. Researchers will track whether or not this information is used in routine health care to make prescribing decisions and the reasons behind whether or not the decision support was used.

Personalized Medicine:

Dr. Gottesman’s work focuses on developing and evaluating tools and best-practices that will facilitate the translation and implementation of genomic and data-driven medicine into clinical practice today. Much of this involves the Institute for Personalized Medicine (IPM) BioBank – a clinical cohort of more than 22,000 Mount Sinai Hospital patients that have donated their DNA to an Electronic Medical Record-linked DNA biorepository and have consented to research on a de-identified image of their medical record and to re-contacting for clinical trials. His work at the IPM has included clinical data representation and electronic phenotyping – creating case definition algorithms that leverage information from the electronic medical record to automatically assign case and control status for use in Genome Wide Association Studies (GWAS), replication studies and implementation trials. He is a co-investigator for a NHGRI U01 consortium - eMERGE II (Electronic MEdical Records and GEnomics). His focus is predominantly on complex trait genomics and pharmacogenomics as they relate to the general medical patient and in clinical data capture and representation.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Gottesman during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Regeneron Pharmaceuticals

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Ontomics, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 18 Room 80
1468 Madison Avenue
New York, NY 10029